Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Pancho Villa who wrote (479)	12/22/1997 9:00:00 AM
From: PawPr	Respond to of 965

Ah Brazil! Great place, gorgeous women ( sorry to anyone I've offended with that sexist remark ); was there in September...learned to samba! Hoped you dumped NEO in time. I'm sure your friend didn't get $12,000/patient ENROLLED in the study; rather, probably $12,000 for each patient who COMPLETED the study. These trials are very, very time consuming and involve a phenomenal amount of paperwork, hence the expense, although $12,000/patient is way higher than anything I'm familiar with.

To: Pancho Villa who wrote (479)	12/22/1997 9:45:00 AM
From: FNS	Read Replies (1) \| Respond to of 965

Pancho: Brazil...Magnifico!!! Have a great time and Buon Natale! CNTO will do well today -- Merrill Lynch upgrades to BUY with a $42 price in 12 months so I just heard. (I'll read the report in a few minutes!) Re: IPIC, <<It is interesting to read in the IPIC thread that some people, including some doctors, think the drug should get approved on a "why not give the patient Citicoline"?, on the basis that if it does no good it will do no harm either>> Perhaps BRUCE might comment on this! I would think that the FDA is sensitive to cost effectiveness in addition to efficacy! We have enough drugs on the market that don't really grow hair or shed fat. FNS